Industry

DUBLIN–(BUSINESS WIRE)–The “Injectable Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information about the Injectable Drug Delivery pipeline products with comparative analysis of the products at various stages of development and information about … [Read more…]

HOUSTON–(BUSINESS WIRE)–Vyripharm Enterprises Inc. and BIZPAC.US hosted the First Annual Vyripharm Public Health and Safety Legislative Reception on August 31, 2022 at the Texas Medical Center (TMC) Institute Innovation Factory, TMC’s 1st phase biotech incubator and accelerator. The purpose of the event was to brief Texas State and Federal legislative members on the importance of … [Read more…]

BRISTOL, N.J. & SEOUL–(BUSINESS WIRE)–Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid … [Read more…]

Ten EVS technicians will each receive $2,500 through Cintas’ third-annual EVS award program CINCINNATI–(BUSINESS WIRE)–In honor of Environmental Services (EVS) week, which is being recognized September 11-17, Cintas Corporation (Nasdaq: CTAS) is proud to announce the winners of its 2022 C.A.P.E. Awards. These awards were established to recognize professionals “Cleaning to Advance the Patient Experience.” … [Read more…]

10th annual MedAxiom cardiovascular provider compensation and production report reveals year-over-year comparisons and decade trends NEPTUNE BEACH, Fla.–(BUSINESS WIRE)–MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 10th annual Cardiovascular Provider Compensation and Production Survey Report that includes data from the largest number of providers since its debut. The report features a … [Read more…]

EARTH CITY, Mo.–(BUSINESS WIRE)–Optime Care, a nationally recognized specialty pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces its support of the inaugural Gene Therapy and Specialty Pharmacy Awareness month, September 2022. The observance is included in the annual Calendar of Health Observances & Recognition Days, … [Read more…]

The addition of Daylight for anxiety and Sleepio for insomnia expands access to evidence-based digital cognitive behavioral therapy to thousands of Americans SAN FRANCISCO–(BUSINESS WIRE)–Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that Daylight for anxiety and Sleepio for insomnia have been added to the Evernorth … [Read more…]

Zerigo Health’s latest software release includes integrated, guideline-recommended phototherapy dosing protocols for the treatment of atopic dermatitis (commonly referred to as eczema), in addition to its existing protocols for psoriasis Evernorth, Cigna’s health services business, will offer Zerigo’s solution as part of a pilot program through its Digital Health Formulary and is the first to … [Read more…]

Applies violeds technology developed by Seoul Viosys, the world’s number one UV LED company Removes up to 99.9% of harmful germs (E.coli, staphylococcus aureus, and pneumococci) within 10 minutes with UVC Seoul Viosys offers optimized disinfection solutions, operating its own auto lab. ANSAN, South Korea–(BUSINESS WIRE)–#GenesisG90–UV-C disinfection technology solution, Violeds, developed by Seoul Semiconductor Co., … [Read more…]

PHILADELPHIA–(BUSINESS WIRE)–Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug (RPD) designation for ABX1100, an investigational Centyrin-siRNA conjugate that targets the Gys1 gene in muscle, for the treatment of Pompe disease. Pompe disease is a rare and deadly … [Read more…]